相似文献
1
Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment.
World J Hepatol. 2012 Dec 27;4(12):327-31. doi: 10.4254/wjh.v4.i12.327.
2
Nonalcoholic fatty liver disease and the renin-angiotensin system blockers in the patients with chronic kidney disease.
Wien Klin Wochenschr. 2015 May;127(9-10):355-62. doi: 10.1007/s00508-014-0661-y. Epub 2014 Nov 21.
3
Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.
Am J Kidney Dis. 2016 May;67(5):728-41. doi: 10.1053/j.ajkd.2015.10.011. Epub 2015 Nov 18.
4
Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Clin Ther. 2007 Sep;29(9):1803-24. doi: 10.1016/j.clinthera.2007.09.019.
5
ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial.
Curr Med Res Opin. 2009 Sep;25(9):2287-301. doi: 10.1185/03007990903152045.
6
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines.
Ann Pharmacother. 2010 Feb;44(2):360-6. doi: 10.1345/aph.1M312. Epub 2010 Jan 19.
7
Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
Drugs. 2010 Jul 9;70(10):1215-30. doi: 10.2165/11537910-000000000-00000.
8
New approaches to blockade of the renin-angiotensin-aldosterone system: evidence from randomized controlled trials (RCTs) of angiotensin-converting enzyme inhibitors and angiotensin II-receptor blockers--questions remain unsolved.
J Pharmacol Sci. 2010;113(4):292-5. doi: 10.1254/jphs.10r08fm. Epub 2010 Jul 27.
9
Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
Expert Opin Pharmacother. 2007 Apr;8(5):529-35. doi: 10.1517/14656566.8.5.529.
10
Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease.
Liver Int. 2015 Mar;35(3):979-85. doi: 10.1111/liv.12611. Epub 2014 Jul 5.
引用本文的文献
1
Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention.
Int J Mol Sci. 2025 Aug 21;26(16):8081. doi: 10.3390/ijms26168081.
2
The Role of Aldosterone and the Mineralocorticoid Receptor in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Biomedicines. 2025 Jul 22;13(8):1792. doi: 10.3390/biomedicines13081792.
3
Liver-targeted degradation of BRD4 reverses hepatic fibrosis and enhances metabolism in murine models.
Theranostics. 2025 Jun 18;15(15):7270-7290. doi: 10.7150/thno.113852. eCollection 2025.
4
Risk Factors for MAFLD and Advanced Liver Fibrosis in Adult-Onset Craniopharyngioma Patients: A Cross-Sectional Study.
Diabetes Metab Syndr Obes. 2025 Mar 25;18:859-871. doi: 10.2147/DMSO.S504968. eCollection 2025.
5
Directional Temporal Relationship Between Hypertension and Non-Alcoholic Fatty Liver Disease: A Cross-Lagged Cohort Study.
J Clin Hypertens (Greenwich). 2025 Feb;27(2):e70012. doi: 10.1111/jch.70012.
6
Molecular dissection of the role of ACE2 in glucose homeostasis.
Physiol Rev. 2025 Jul 1;105(3):935-973. doi: 10.1152/physrev.00027.2024. Epub 2025 Feb 7.
7
The effect of different treatment strategies on glycolipid metabolism disorders and cardiovascular events in primary aldosteronism.
Hypertens Res. 2024 Jun;47(6):1719-1727. doi: 10.1038/s41440-024-01648-0. Epub 2024 Apr 2.
8
Association between use of vitamin and mineral supplement and non-alcoholic fatty liver disease in hypertensive adults.
Sci Rep. 2023 Aug 22;13(1):13670. doi: 10.1038/s41598-023-40868-1.
9
Therapies for patients with coexisting heart failure with reduced ejection fraction and non-alcoholic fatty liver disease.
World J Cardiol. 2023 Jul 26;15(7):328-341. doi: 10.4330/wjc.v15.i7.328.
10
The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease.
Curr Obes Rep. 2023 Sep;12(3):191-206. doi: 10.1007/s13679-023-00519-y. Epub 2023 Jul 5.
本文引用的文献
1
Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial.
Hepatology. 2011 Nov;54(5):1631-9. doi: 10.1002/hep.24558.
2
The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort.
Dig Dis Sci. 2011 Feb;56(2):564-8. doi: 10.1007/s10620-010-1507-8. Epub 2010 Dec 7.
3
4
Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice.
Diabetologia. 2010 Aug;53(8):1727-31. doi: 10.1007/s00125-010-1744-6.
5
Effect of valsartan on the incidence of diabetes and cardiovascular events.
N Engl J Med. 2010 Apr 22;362(16):1477-90. doi: 10.1056/NEJMoa1001121. Epub 2010 Mar 14.
6
Role of angiotensin II in liver fibrosis-induced portal hypertension and therapeutic implications.
Hepatol Res. 2010 Jan 1;40(1):95-104. doi: 10.1111/j.1872-034X.2009.00581.x. Epub 2009 Sep 7.
7
Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C.
Am J Physiol Gastrointest Liver Physiol. 2009 Oct;297(4):G726-34. doi: 10.1152/ajpgi.00162.2009. Epub 2009 Jul 23.
8
Angiotensin II antagonists in patients with recurrent hepatitis C virus infection after liver transplantation.
Liver Int. 2010 Feb;30(2):334-5. doi: 10.1111/j.1478-3231.2009.02059.x. Epub 2009 Jun 9.
9
Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue.
Liver Int. 2009 Aug;29(7):988-96. doi: 10.1111/j.1478-3231.2009.02006.x. Epub 2009 Apr 6.
10
Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis.
World J Gastroenterol. 2009 Feb 28;15(8):942-54. doi: 10.3748/wjg.15.942.
Zotero 插件